The United States Supreme Court has declined to hear appeals from several pharmaceutical corporations challenging the federal government's authority to negotiate drug pricing within the Medicare program.

美國最高法院已拒絕受理數家製藥公司的上訴，這些公司此前對聯邦政府在 Medicare 計畫中協商藥品價格的權限提出挑戰。

The judicial determination serves to uphold prior rulings from the federal appeals court in Philadelphia, which had previously dismissed the claims brought by entities including AstraZeneca, Novo Nordisk, and Bristol Myers Squibb. This legal framework is predicated upon the 2022 Inflation Reduction Act, a legislative instrument that authorized the federal government to conduct annual price negotiations for specific high-cost pharmaceuticals. The initial implementation of these negotiated rates is scheduled for 2026.

此次司法裁定維持了費城聯邦上訴法院之前的裁決，該裁決先前已駁回包括 AstraZeneca、Novo Nordisk 及 Bristol Myers Squibb 等實體的訴求。此法律框架基於 2022 年的《通貨膨脹削減法案》，該立法工具授權聯邦政府對特定高成本藥品進行年度價格談判。這些協商價格預計將於 2026 年開始實施。

Political divergence regarding this authority remains evident, as the legislation lacked Republican support during its inception. While the current administration has actively utilized these powers—having already negotiated prices for 25 medications, including GLP-1 agonists such as Ozempic and Wegovy—previous executive actions under President Trump sought the curtailment of other Inflation Reduction Act provisions. The administration has further expanded the program's scope, announcing a third round of negotiations intended to increase the total number of affected pharmaceuticals to 40.

關於此權限的政治分歧依然明顯，因為該法案在啟動之初缺乏共和黨的支持。雖然現任政府積極行使這些權力——已為 25 種藥物協商價格，包括 Ozempic 和 Wegovy 等 GLP-1 受體激動劑——但川普總統時期的行政行動曾試圖縮減《通貨膨脹削減法案》的其他條款。政府進一步擴大了計劃範圍，宣布第三輪談判，旨在將受影響的藥品總數增加至 40 種。

Industry stakeholders have posited that the objective of cost reduction should be pursued through the regulation of third-party pharmacy benefit managers and insurers rather than direct price negotiation. However, given the absence of a specified expiration date within the statute and the current judicial refusal to intervene, the cessation of the program would necessitate a legislative act of Congress.

產業相關人士認為，降低成本的目標應透過監管第三方藥局福利管理公司及保險公司來實現，而非直接進行價格協商。然而，鑑於法律中未規定具體的到期日期，且目前司法機關拒絕干預，要終止該計劃將需要國會採取立法行動。

The Supreme Court's refusal to intervene ensures the continued operation of the Medicare price negotiation program as established by federal law.

最高法院拒絕干預，確保了由聯邦法律確立的 Medicare 價格協商計畫能持續運作。